Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Newswire.ca
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of CRT vs Chemotherapy for Locally Advanced Endometrial Carcinoma - MedPage Today
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of CRT vs Chemotherapy for Locally Advanced Endometrial Carcinoma MedPage Today
Curcumin-gold nanoshell mediated near-infrared irradiation on human ovarian cancer cell: in vitro study.
Ovarian cancer is considered a predominant female reproductive malignancy and poses a significant threat due to its 80-90% fatality rate. The typical approach involves surgery and chemotherapy, which due to …
Targeting ferroptosis for the treatment of female reproductive system disorders.
Ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, has emerged as a critical factor in female reproductive health and has been implicated in disorders such as …
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial - Nature.com
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial Nature.com
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial - Medpage Today
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial Medpage Today